If you’ve spent any time on health news this week, you’ve probably seen the headlines: a new daily pill is being talked about as a potential alternative to weekly weight-loss injections. As an independent pharmacist serving families across Bulloch and Toombs Counties for years, I’ve been fielding a lot of questions at our counters in Statesboro, Brooklet, and Lyons. So let’s slow down and look at what was actually published.

On May 12, 2026, Nature Medicine released the full results of the ATTAIN-MAINTAIN trial, a phase 3b study evaluating orforglipron — sold under the brand name Foundayo — in patients who had already lost weight on injectable GLP-1 medications. The FDA approved Foundayo in April 2026, and this new data is one of the biggest reasons the conversation is heating up.

What Is Orforglipron (Foundayo)?

Orforglipron is a once-daily oral GLP-1 receptor agonist made by Eli Lilly. Unlike Ozempic, Wegovy, Mounjaro, and Zepbound — all of which are injectable peptides — orforglipron is a small-molecule pill. According to Eli Lilly’s announcement and reporting from Pharmacy Times, it is the first GLP-1 weight-loss pill that can be taken any time of day, with or without food and water restrictions. That’s a meaningful difference from earlier oral GLP-1 attempts.

The FDA approved Foundayo for adults with obesity, or those who are overweight with weight-related medical conditions, when used alongside a reduced-calorie diet and increased physical activity. In the initial trials, orforglipron delivered an average of about 12.4% body weight loss at the highest dose. That’s lower than the peak numbers we’ve seen from tirzepatide (Zepbound) but in the same general ballpark as some doses of semaglutide.

What the ATTAIN-MAINTAIN Trial Found

The ATTAIN-MAINTAIN trial, published in Nature Medicine on May 12 and summarized by Weill Cornell Medicine and the Pharmacy Times news desk, asked a very practical question: if someone has already lost weight on an injectable, can they switch to the oral pill and keep most of that weight off?

Here’s the setup: 205 patients on tirzepatide and 171 patients on semaglutide were randomly assigned to take either orforglipron or a placebo daily for one year, after having achieved weight loss on their injectable.

The results, as reported in Nature Medicine and summarized by Drug Topics:

• Patients who switched from tirzepatide to orforglipron maintained an average of 74.7% of their weight loss, compared to 49.2% in the placebo group.
• Patients who switched from semaglutide to orforglipron maintained an average of 79.3% of their weight loss, versus 37.6% on placebo.
• Patients also held onto cardiometabolic improvements — reduced waist circumference and better blood pressure, blood sugar, triglyceride, and cholesterol readings.
• Side effects were mild to moderate and mostly gastrointestinal, consistent with what we expect from the GLP-1 class.

In plain English: switching from a weekly injection to a daily pill helped most patients hold onto the majority of their progress over a year. That’s a real finding, and it matters for patients who struggle with injections, supply issues, or cost.

Why This Matters for Patients in Southeast Georgia

I’ll be straight with you. In a small-town pharmacy like ours, the conversation about GLP-1 medications has been complicated. We’ve seen patients excited about results, frustrated by shortages, and shocked by out-of-pocket costs. We’ve also watched patients regain weight when they stopped a medication — sometimes because their insurance changed, sometimes because they couldn’t get the injection consistently.

An oral GLP-1 that doesn’t require refrigeration, doesn’t need food-timing precision, and doesn’t involve a weekly self-injection is a real practical change. It could expand who is willing — and able — to start treatment. But “different delivery method” doesn’t mean “different drug class.” Orforglipron is still a GLP-1 receptor agonist with the same general risk profile.

A Pharmacist’s Perspective

Here’s what I’d tell you if you walked up to the counter in Statesboro and asked about Foundayo.

First, this is genuinely interesting data, and it’s good news for people who have tolerated injectable GLP-1s but want a simpler routine. Second, we are still early. The ATTAIN-MAINTAIN trial is one year long. The long-term safety and effectiveness data — five years, ten years — simply do not exist yet for orforglipron. That isn’t a criticism of the drug; it’s a fact about how new it is.

Third, the people who did best in the trial were people who had already lost weight on another GLP-1 and then transitioned. That’s not the same population as someone starting from scratch. The 12.4% average weight loss figure from the initial trials is meaningful but smaller than tirzepatide’s peak numbers.

Fourth, gastrointestinal side effects — nausea, constipation, occasional vomiting — are common across all GLP-1s, including this one. They’re usually manageable but they’re real, and they’re often why people stop.

Fifth, and this is the big one: a GLP-1 is a tool, not a strategy. The trial protocol included diet and physical-activity counseling. The medication works best in the context of broader changes. I’m not telling you that lifestyle alone fixes obesity — the evidence is clear that for many people it doesn’t — but I am telling you that no pill, oral or injected, is a substitute for working with a clinician who knows your full picture.

Whether Foundayo, Ozempic, Wegovy, Mounjaro, Zepbound, or none of the above is right for you is not a question I — or any pharmacist — can answer in a single conversation. That’s a decision for you and your prescribing physician, and we’re glad to be part of the team.

Frequently Asked Questions

Is Foundayo (orforglipron) available at Walker Pharmacy?

Foundayo received FDA approval in April 2026, and availability is rolling out. We’re tracking supply closely. If your physician is considering it for you, call any of our locations and we’ll let you know the current status and pricing.

How is Foundayo different from Ozempic or Wegovy?

Ozempic and Wegovy (both semaglutide) are weekly injections. Foundayo (orforglipron) is a once-daily pill that can be taken any time of day, with no food or water timing restrictions. All three are GLP-1 receptor agonists, but they are different molecules with different dosing and different evidence bases. Effectiveness comparisons are still emerging.

Can I switch from a GLP-1 injection to the oral pill?

The ATTAIN-MAINTAIN trial suggests this is possible and that most patients keep the majority of their weight loss when they switch. But switching medications is a clinical decision. Talk to your prescribing physician before changing anything, and we’re happy to help review the prescription details with you.

What are the most common side effects?

Based on the published trials, the most common side effects are gastrointestinal: nausea, diarrhea, constipation, and occasionally vomiting. These are usually mild to moderate and often improve over time, but they can be significant for some people.

Will my insurance cover it?

Coverage for GLP-1 medications varies widely by plan and by indication (diabetes versus weight loss). Walker Pharmacy can run a benefit check for you — just bring your insurance information by any of our four locations.

Come Talk to Us

If you’ve been reading the news about Foundayo, orforglipron, or any of the GLP-1 medications and wondering what it means for you, come see us. We don’t rush conversations at Walker Pharmacy. We’re a second-generation family pharmacy, and we treat every prescription like it belongs to a neighbor — because in Statesboro, Brooklet, and Lyons, it usually does.

If you’d like us to handle your prescriptions going forward, we make it easy to transfer. Transfer your prescriptions to Walker Pharmacy here, or give any of our locations a call.

This article is for informational purposes only and does not constitute medical or health advice. Always consult your physician or pharmacist before making changes to your health regimen.

— Jordan Walker, PharmD | Owner, Walker Pharmacy